X

Trial Profile

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

28 Mar 2023 Planned primary completion date changed from 1 May 2022 to 1 May 2024.
11 Mar 2021 Planned primary completion date changed from 1 Nov 2021 to 1 May 2022.
11 Mar 2021 Planned initiation date (Estimated date of first participant enrollment) changed from 1 Nov 2020 to 1 May 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com